Q4 Earnings Estimate for NAGE Issued By HC Wainwright

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Equities researchers at HC Wainwright issued their Q4 2025 EPS estimates for Niagen Bioscience in a research note issued on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $0.02 per share for the quarter. HC Wainwright also issued estimates for Niagen Bioscience’s Q2 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.13 EPS.

Other analysts also recently issued reports about the company. Canaccord Genuity Group decreased their price target on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Niagen Bioscience currently has a consensus rating of “Moderate Buy” and an average price target of $14.28.

Niagen Bioscience Stock Performance

Shares of NAGE stock opened at $4.94 on Thursday. Niagen Bioscience has a 52-week low of $4.84 and a 52-week high of $14.69. The company has a 50-day simple moving average of $6.06 and a two-hundred day simple moving average of $7.50. The company has a market capitalization of $394.26 million, a price-to-earnings ratio of 20.58 and a beta of 2.35.

Institutional Trading of Niagen Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC bought a new position in Niagen Bioscience in the 3rd quarter worth about $1,169,000. BSW Wealth Partners purchased a new position in Niagen Bioscience during the third quarter valued at approximately $793,000. CWM LLC purchased a new position in Niagen Bioscience during the third quarter valued at approximately $246,000. Precision Wealth Strategies LLC bought a new stake in Niagen Bioscience during the 3rd quarter worth approximately $1,527,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Niagen Bioscience in the 3rd quarter worth approximately $144,000. 15.41% of the stock is currently owned by institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.